BamSEC and AlphaSense Join Forces
Learn More

4D Molecular Therapeutics Inc.

NASDAQ: FDMT    
Share price (12/20/24): $6.31    
Market cap (12/20/24): $292 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.17
from 10-K 14 pages 4D Molecular Therapeutics, Inc. Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.16
from 10-K 15 pages Background
12/34/56
EX-10.15
from 10-K 15 pages Background
12/34/56
EX-10.14
from 10-K 5 pages Material contract
12/34/56
EX-10.1
from 10-Q 64 pages License Agreement Between 4D Molecular Therapeutics, Inc. and Astellas Gene Therapies, Inc. Dated as of July 5, 2023 License Agreement
12/34/56
EX-10.1
from 10-Q 4 pages 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.4
from 10-Q 11 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.3
from 8-K 12 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.2
from 8-K 12 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.1
from 8-K 12 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.12
from S-1/A 5 pages January 4, 2019 August Moretti [*****] Dear August: We Are Pleased to Make You the Following Offer of Employment. We Believe You Will Play an Important and Meaningful Role in Our Mission of Curing People of Genetic Diseases
12/34/56
EX-10.11
from S-1/A 15 pages 4D Molecular Therapeutics, Inc. Employment Agreement
12/34/56
EX-10.10
from S-1/A 4 pages Material contract
12/34/56
EX-10.9
from S-1/A 32 pages Exclusive License and Bailment Agreement Between 4D Molecular Therapeutics, LLC and the Regents of the University of California for Adeno-Associated Virus Variants for Enhanced Gene Delivery in the Presence of Neutralizing Antibodies
12/34/56
EX-10.8
from S-1/A 34 pages Exclusive License and Bailment Agreement Between 4D Molecular Therapeutics, LLC and the Regents of the University of California for Adeno-Associated Virus Serotype 2 (Aav2) Capsid Mutants With Novel Properties for Enhanced Performance for Gene Therapy
12/34/56
EX-10.4
from S-1/A 16 pages 4D Molecular Therapeutics, Inc. Indemnification Agreement
12/34/56
EX-10.3
from S-1/A 14 pages 4D Molecular Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.2(D)
from S-1/A 5 pages 4D Molecular Therapeutics, Inc. 2020 Incentive Award Plan Restricted Stock Unit Award Grant Notice
12/34/56
EX-10.2(C)
from S-1/A 5 pages 4D Molecular Therapeutics, Inc. 2020 Incentive Award Plan Restricted Stock Award Grant Notice
12/34/56
EX-10.2(B)
from S-1/A 9 pages 4D Molecular Therapeutics, Inc. 2020 Incentive Award Plan Stock Option Grant Notice
12/34/56